Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Mussetti

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|May 7, 2026
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committeeRoser Velasco, Martin Schmidt-Hieber, Olaf Penack, et al.
Blood|December 17, 2015
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsAbraham S Kanate, Alberto Mussetti, Mohamed A Kharfan-Dabaja, et al.
Bone Marrow Transplantation|May 25, 2022
Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantationJesus Fernandez-Sojo, Joan Cid, Carmen Azqueta, et al.
Transplantation and Cellular Therapy|July 28, 2024
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMORebeca Bailén, Gloria Iacoboni, Javier Delgado, et al.
Haematologica|June 30, 2022
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphomaMi Kwon, Gloria Iacoboni, Juan Luis Reguera, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Frontiers in Immunology|January 22, 2025
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and careMaría Queralt Salas, María Teresa Solano, Mónica Baile González, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2019
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaSairah Ahmed, Jennifer A Kanakry, Kwang W Ahn, et al.
Transplantation and Cellular Therapy|January 14, 2026
Haploidentical Donor vs. Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplant, a GETH-TC StudyMaría Laura Fox, Ariadna Pérez Martínez, Albert Esquirol, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|May 7, 2026
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committeeRoser Velasco, Martin Schmidt-Hieber, Olaf Penack, et al.
Blood|December 17, 2015
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsAbraham S Kanate, Alberto Mussetti, Mohamed A Kharfan-Dabaja, et al.
Bone Marrow Transplantation|May 25, 2022
Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantationJesus Fernandez-Sojo, Joan Cid, Carmen Azqueta, et al.
Transplantation and Cellular Therapy|July 28, 2024
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMORebeca Bailén, Gloria Iacoboni, Javier Delgado, et al.
Haematologica|June 30, 2022
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphomaMi Kwon, Gloria Iacoboni, Juan Luis Reguera, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Frontiers in Immunology|January 22, 2025
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and careMaría Queralt Salas, María Teresa Solano, Mónica Baile González, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2019
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaSairah Ahmed, Jennifer A Kanakry, Kwang W Ahn, et al.
Transplantation and Cellular Therapy|January 14, 2026
Haploidentical Donor vs. Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplant, a GETH-TC StudyMaría Laura Fox, Ariadna Pérez Martínez, Albert Esquirol, et al.
Pageof 10